Ashwani Verma
Stock Analyst at UBS
(3.95)
# 773
Out of 5,182 analysts
110
Total ratings
54.32%
Success rate
10.11%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $36 → $42 | $34.95 | +20.17% | 11 | Apr 30, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $51 → $57 | $49.47 | +15.22% | 4 | Apr 21, 2026 | |
| AMRX Amneal Pharmaceuticals | Initiates: Buy | $19 | $12.83 | +48.09% | 1 | Apr 17, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $251 → $259 | $206.53 | +25.41% | 8 | Apr 10, 2026 | |
| INCY Incyte | Maintains: Neutral | $104 → $94 | $96.91 | -3.00% | 3 | Mar 25, 2026 | |
| ALVO Alvotech | Maintains: Buy | $10 → $6 | $3.46 | +73.41% | 2 | Mar 24, 2026 | |
| CYTK Cytokinetics | Maintains: Neutral | $61 → $69 | $63.35 | +8.92% | 6 | Mar 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $655 → $705 | $570.40 | +23.60% | 12 | Mar 5, 2026 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Neutral | $43 → $46 | $31.83 | +44.52% | 4 | Feb 11, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $178 | $131.78 | +35.07% | 11 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $223 → $215 | $133.26 | +61.34% | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $40 | $21.95 | +82.23% | 9 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $95 | $51.42 | +84.75% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $48 | $23.59 | +103.48% | 4 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $26 → $11 | $9.63 | +14.23% | 5 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $163 → $188 | $202.72 | -7.26% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $206.60 | +6.49% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $43.68 | -8.42% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $27.12 | -33.63% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $33.38 | +25.82% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.80 | -41.67% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $329.50 | -97.88% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $15.04 | -20.21% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.94 | +1,495.74% | 1 | Oct 11, 2022 |
Teva Pharmaceutical Industries
Apr 30, 2026
Maintains: Buy
Price Target: $36 → $42
Current: $34.95
Upside: +20.17%
Royalty Pharma
Apr 21, 2026
Maintains: Buy
Price Target: $51 → $57
Current: $49.47
Upside: +15.22%
Amneal Pharmaceuticals
Apr 17, 2026
Initiates: Buy
Price Target: $19
Current: $12.83
Upside: +48.09%
Axsome Therapeutics
Apr 10, 2026
Maintains: Buy
Price Target: $251 → $259
Current: $206.53
Upside: +25.41%
Incyte
Mar 25, 2026
Maintains: Neutral
Price Target: $104 → $94
Current: $96.91
Upside: -3.00%
Alvotech
Mar 24, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $3.46
Upside: +73.41%
Cytokinetics
Mar 6, 2026
Maintains: Neutral
Price Target: $61 → $69
Current: $63.35
Upside: +8.92%
United Therapeutics
Mar 5, 2026
Maintains: Buy
Price Target: $655 → $705
Current: $570.40
Upside: +23.60%
Harmony Biosciences Holdings
Feb 11, 2026
Downgrades: Neutral
Price Target: $43 → $46
Current: $31.83
Upside: +44.52%
Neurocrine Biosciences
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $131.78
Upside: +35.07%
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $133.26
Upside: +61.34%
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $21.95
Upside: +82.23%
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $51.42
Upside: +84.75%
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $23.59
Upside: +103.48%
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $9.63
Upside: +14.23%
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $202.72
Upside: -7.26%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $206.60
Upside: +6.49%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $43.68
Upside: -8.42%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $27.12
Upside: -33.63%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $33.38
Upside: +25.82%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.80
Upside: -41.67%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $329.50
Upside: -97.88%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $15.04
Upside: -20.21%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.94
Upside: +1,495.74%